Titan Shares Rise After FDA Panel Backs Opioid Implant

Bloomberg Businessweek

Titan Pharmaceuticals Inc. (TTNP) rose the most in almost four years after U.S. regulatory advisers recommended approval for the company’s experimental implant to treat addiction to heroin and prescription painkillers. Titan increased (TTNP) 38 percent to $1.70 at 9:56 a.m. New York time. The stock reached $1.90, for its biggest intraday gain since May 7, 2009. The Food and Drug Administration is scheduled to decide by April 30 whether to approve the treatment.

Full Article >